Latest News - Moderna
Top Corporates Hub
Moderna
Investing.com’s stocks of the week
23.10.2026 18:29
Investing.com -- Cybersecurity names gained ground on a global software alert while Meta declined and a fresh escalation in the Middle East pushed crude to highs.
Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?
23.10.2026 16:11
Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data.
Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’
23.10.2026 15:33
In an interview with CNBC, Merck CEO Rob Davis said the company is confident it can deliver Intismeran at scale.
Decker Outdoor Tumbles on Guidance; Amex to Cut Workforce | Stock Movers
23.10.2026 15:32
On this episode of Stock Movers: - Decker Outdoor (DECK) is tumbling after the footwear company cut its net sales guidance for the full year, which also fell short of the consensus estimate. - Kering (KER) shares are slumping after the French luxury-goods company saw further deceleration of third-quarter revenue growth at its key Gucci unit, slower growth in North America as well as persistent weakness in China. - American Express (AXP) shares are moving on news that the company is planning to cut 5% of its global headcount. Chief Executive Officer Steve Squeri told Bloomberg TV that the move will affect about 3,500 jobs. - Moderna (MRNA) plummeted after data on the companies' widely anticipated melanoma vaccine wasn't enough to prove to investors that a new era of cancer treatments has arrived. While the results clearly showed the vaccine worked, they weren't spectacular enough to generate confidence.
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
23.10.2026 15:08
Moderna falls despite positive phase III cancer therapy data showing reduced melanoma recurrence and metastasis risks, as investors weigh elevated expectations.
Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?
23.10.2026 14:15
The stock fell 17% in one trading session.
Moderna’s Cancer-Vaccine Data Leak Spurs Panic Selling. Wall Street Wanted a Cure.
23.10.2026 14:06
Moderna and Merck’s cancer vaccine reduced the risk of melanoma recurrence or death by 42%, but investors questioned its potential across other cancers.
Moderna’s Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure
23.10.2026 14:06
Moderna and Merck’s cancer vaccine reduced the risk of melanoma recurrence or death by 42%, but investors questioned its potential across other cancers.
Moderna trims losses as investors digest melanoma vaccine trial data
23.10.2026 13:49
Moderna stock stabilized on Friday, reversing the prior session's steep sell-off.
Moderna stock extends decline after leaked data on melanoma vaccine trial
23.10.2026 13:49
Moderna stock sank as Wall Street grew more cautious on the company's valuation after a massive rally this year.
ESMO26: MSD and Moderna drop cancer vaccine trial data early
23.10.2026 12:54
The results were leaked two days before their scheduled presentation at the first Presidential Symposium of ESMO 2026.
US Stock Market Today: S&P 500 Futures Steady On Strong Jobs And PMI Focus
23.10.2026 12:12
The Morning Bull - US Market Morning Update Friday, Oct, 23 2026 US stocks look set for a cautiously positive open, with S&P 500 futures hovering slightly higher. The single driver this morning is labor strength, as fresh jobless claims signal a still resilient employment backdrop. Initial unemployment claims came in at 194,000 for the week ended October 17, the lowest level since July. Continuing claims held at 1.728 million. Together, those figures point to limited layoffs and ongoing...
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
23.10.2026 11:00
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year. Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment.
Moderna Sinks 18% on Leaked Melanoma Data: “Benefit Was Greater After Six Months”
23.10.2026 05:58
Moderna (MRNA:NASDAQ) stock sank 17. 6% on Thursday to close at $202.
Moderna Slides Up to 25% as Cancer Vaccine Meets Sky-High Expectations
23.10.2026 04:51
Moderna fell up to 25% despite a cancer vaccine that cut melanoma recurrence or death risk 42%, as expectations ran high.
After Moderna's 672% Climb, The Story Has Changed
23.10.2026 04:26
Moderna spent much of 2025 caught between bullish hopes for mRNA expansion and bearish warnings about shrinking COVID demand and tighter pricing. For Moderna shareholders, the return over the past year was 671.9%, including dividends. If you had been weighing those sharply different analyst views in October 2025, how would you have judged the odds that such an extreme outcome could follow from the business that was on record then? The move put Moderna in the middle of this trade. Scan 36...
Why Moderna (MRNA) stock is trading lower today
23.10.2026 02:05
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its personalized cancer vaccine leaked ahead of a planned presentation this weekend, and the stock sold off hard even though the results themselves look positive. According to CNBC, shares fell as much as 25% after an early look at the vaccine Moderna is developing with Merck, intismeran autogene, showed up online before it was supposed to be presented at the Eur
MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings
23.10.2026 01:28
Mizuho analyst Jared Holz said the vaccine data weren’t bad, but Wall Street’s expectations were too high.
Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says
23.10.2026 00:18
Moderna shares tumbled after leaked cancer vaccine trial data showed promising results for its treatment developed with Merck.
FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study
22.10.2026 10:25
The FDA lifts its 3-year clinical hold on Arbutus Biopharma's AB-101 hepatitis B drug candidate, clearing US clinical trials.